Compounds / Metabolic / AOD-9604

AOD-9604

Anti-Obesity Drug 9604 (hGH Fragment 176–191)
MetabolicExtensively StudiedFDA: Not approved; FDA PCAC reviewed 2024

Overview

Clinical trials: ~2.6 kg vs 0.8 kg placebo over 12 weeks. Placebo-like safety profile. No anti-AOD antibodies. FDA PCAC reviewed 2024.

Mechanism of Action

C-terminal hGH fragment retaining lipolytic domain without growth-promoting effects. Binds adipose tissue, triggers lipolysis, inhibits lipogenesis. Upregulates β3-adrenergic receptors. Does not elevate IGF-1.

Pharmacokinetics

Half-life
30 min
Peak (Tmax)
15 min
Cleared
~2.5 hrs

Molecular Profile

Molecular weight
1,815.1 Da
CAS number
221231-10-3
Type
Modified hGH C-terminal fragment
Length
17 amino acids
YLRIVQCRSVEGSCGF (Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe)

Key Research Findings

Preferential abdominal fat loss; no IGF-1 elevation; placebo-like safety; emerging cartilage repair data.

Published Research

J Endocrinol Metab (2014)
Safety and metabolism of AOD9604 as nutraceutical ingredient
View source
FDA.gov
AOD-9604 FDA PCAC meeting memorandum 2024
View source

Related Metabolic Compounds

SemaglutideTirzepatideRetatrutideCagrilintideMazdutideBioglutide
Clinical Guidance

Research data is not a treatment plan. If you are considering AOD-9604, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.
Running AOD-9604? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator  ·  Full deep dive  ·  Peptide fundamentals